Company InfoNewsInvestor InformationResearchDevelopmentCareersBusiness DevelopmentResourcesDrugs databaseBack to the home pageSearch  
Drugs database
Drugs A-Z

Brands A-Z

Drugs by categories

Drugs by manufacturer

Drugs by packager

Antibiotics for sale

Online Viagra bestellen in Nederland

Home / Drugs / Starting with P / Penicillamine
 
Penicillamine
 

3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. [PubChem]
BrandsArtamine
Cuprenil
Cuprimine
Cupripen
Depamine
Depen
Distamine
Kuprenil
Mercaptovaline
Mercaptyl
Metalcaptase
Pendramine
Perdolat
Sufirtan
Trolovol
CategoriesAntirheumatic Agents
Chelating Agents
Antidotes
ManufacturersAton pharma inc
Meda pharmaceuticals inc
PackagersAton Pharma Inc.
Draxis Specialty Pharmaceuticals Inc.
Gallipot
Meda AB
Medisca Inc.
Merck & Co.
Patheon Inc.
Synonymsbeta-Thiovaline
beta,beta-Dimethylcysteine
D-Mercaptovaline
D-Penamine
D-Penicilamine
D-Penicillamine
D-Penicyllamine
Dimethylcysteine
L-Penicillamine
Penicilamina [INN-Spanish]
Penicillamin
Penicillamina [DCIT]
Penicillaminum [INN-Latin]
Penicilllamine

indication

For treatment of Wilson's disease, cystinuria and active rheumatoid arthritis.

pharmacology

Penicillamine is a chelating agent used in the treatment of Wilson's disease. It is also used to reduce cystine excretion in cystinuria and to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy. Penicillamine is used as a form of immunosuppression to treat rheumatoid arthritis. It works by reducing numbers of T-lymphocytes, inhibiting macrophage function, decreasing IL-1, decreasing rheumatoid factor, and preventing collagen from cross-linking. Its use in Wilson's disease, a rare genetic disorder of copper metabolism, relies on its binding to accumulated copper and elimination through urine.

mechanism of action

Penicillamine is a chelating agent recommended for the removal of excess copper in patients with Wilson's disease. From in vitro studies which indicate that one atom of copper combines with two molecules of penicillamine. Penicillamine also reduces excess cystine excretion in cystinuria. This is done, at least in part, by disulfide interchange between penicillamine and cystine, resulting in formation of penicillamine-cysteine disulfide, a substance that is much more soluble than cystine and is excreted readily. Penicillamine interferes with the formation of cross-links between tropocollagen molecules and cleaves them when newly formed. The mechanism of action of penicillamine in rheumatoid arthritis is unknown although it appears to suppress disease activity. Unlike cytotoxic immunosuppressants, penicillamine markedly lowers IgM rheumatoid factor but produces no significant depression in absolute levels of serum immunoglobulins. Also unlike cytotoxic immunosuppressants which act on both, penicillamine in vitro depresses T-cell activity but not B-cell activity.

biotransformation

Hepatic

absorption

rapidly but incompletely

half life

1 hour

route of elimination

Excretion is mainly renal, mainly as disulfides.

drug interactions

Digoxin: Penicillamine decreases the effect of digoxin

Iron Dextran: The multivalent agent decreases the effect of penicillamine